Translational Research
Volume 154, Issue 4 , Pages 202-213 , October 2009

Iron sufficient to cause hepatic fibrosis and ascites does not cause cardiac arrhythmias in the gerbil

  • Lana Kaiser

      Affiliations

    • Hematology & Oncology Unit, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Mich
    • Corresponding Author InformationReprint requests: Lana Kaiser MD, DVM, Department of Medicine, B203 Life Sciences Building, Michigan State University, East Lansing, MI 48854
    • ,
  • John M. Davis

      Affiliations

    • Hematology & Oncology Unit, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Mich
    • ,
  • Jon Patterson

      Affiliations

    • Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, Mich
    • ,
  • Abby L. Johnson

      Affiliations

    • Hematology & Oncology Unit, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Mich
    • ,
  • George Bohart

      Affiliations

    • Large Animal Clinical Sciences, Michigan State University, East Lansing, Mich
    • ,
  • N. Bari Olivier

      Affiliations

    • Small Animal Clinical Sciences College or Veterinary Medicine, Michigan State University, East Lansing, Mich
    • ,
  • Kenneth A. Schwartz

      Affiliations

    • Hematology & Oncology Unit, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Mich

Received 19 March 2009 ,Revised 8 July 2009 ,Accepted 9 July 2009.

References 

  1. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol. 2006;81:202–209
  2. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In:  Greer JP,  Foerster J,  Lukens JN,  Rodgers GM,  Paraskevas F,  Glader BE editor. Wintrobe's clinical hematology. 11th ed. Philadelphia, Pa: Williams & Wilkins: Lippincott; 2004;
  3. Borgna-Pignatti C, Rugolotto S, DiPalma A, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci. 1998;850:227–230
  4. Engle MA. Cardiac involvement in Cooley's anemia. Ann NY Acad Sci. 1964;119:694–702
  5. Engle MA, Erlandsom M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30:698–705
  6. Berdoukas V, Modell B. Transfusion-dependent thalassaemia: a new era. Med J Aust. 2008;188:68–69
  7. Modell B, Khan M, Darlison M. Survival in β-thalassemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2052
  8. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J. 1982;284:1081–1084
  9. Ehlers KH, Levin AR, Markenson AL, et al. Longitudinal study of cardiac function in thalassemia major. Ann NY Acad Sci. 1980;344:397–404
  10. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343:1529–1535
  11. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411–3416
  12. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229–1236
  13. Kaye SB, Owen M. Cardiac arrhythmias in thalassaemia major: evaluation of chelation therapy using ambulatory monitoring. Br Med J. 1978;1:342
  14. Modell B, Kahn M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42–49
  15. Carthew P, Dorman B, Edwards RE, Francis JE, Smith AG. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest. 1993;69:217–222
  16. Obejero-Paz CA, Yang T, Dong W, et al. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload. J Lab Clin Med. 2003;141:121–130
  17. Kaiser L, Davis J, Patterson J, et al. Iron does not cause arrhythmias in the guinea pig model of transfusional iron overload. Comp Med. 2007;57:383–389
  18. Yang T, Dong W-Q, Kuryshev YA, et al. Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med. 2002;140:263–271
  19. Yang T, Brittenham GM, Dong WQ, et al. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med. 2003;142:332–340
  20. Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol. 1998;274:H747–H51
  21. Liu G, Iden JB, Kovithavongs K, Gulamhusein R, Duff HJ, Kavanagh KM. 2004. In vivo temporal and spatial distribution of depolarization and repolarization and the illusive murine T wave. J Physiol. 2004;555:267–279
  22. Richards AG, Simonson E, Visscher MB. Electrocardiogram and phonogram of adult and newborn mice in normal conditions and under the effect of cooling, hypoxia and potassium. Am J Physiol. 1953;174:293–298
  23. Ochieng J, Green B, Evans S, James O, Warfield P. Modulation of biological function of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta. 1998;1379:97–106
  24. Zurlo MG, DeStefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1998;2:27–31
  25. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51:209–221
  26. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol. 2003;70:398–403
  27. London B. Cardiac arrhythmias: From (transgenic) mice to men. J Cardiovasc Electrophysiol. 2001;12:1089–1091
  28. Chaves AA, Dech SJ, Nakayama T, Hamlin RL, Bauer JA, Carnes CA. Age and anesthetic effects on murine electrocardiography. Life Sci. 2003;72:2401–2412
  29. Walker EM, Epling CP, Parris C, et al. Acetaminophen protects against iron-induced cardiac damage in gerbils. Ann Clin Lab Sci. 2007;37:22–33
  30. Wood JC, Otto-Duessel M, Gonzalez I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;48:272–280
  31. Hershko C, Link G, Konijn AM, Rosenmann E, Renus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med. 2002;139:50–58
  32. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288–298
  33. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–3128
  34. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103:5060–5065
  35. Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int. 2007;56:57–65
  36. Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Biometals. 1994;7:267–271
  37. Pietrangelo A, Montosi G, Garuti C, et al. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomembr. 2002;34:67–79

 Supported by a grant from the National Blood Foundation (to L.K.).

PII: S1931-5244(09)00216-3

doi: 10.1016/j.trsl.2009.07.002

Translational Research
Volume 154, Issue 4 , Pages 202-213 , October 2009

Article Tools

* Image Usage & Resolution